Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Recruiting · NCT04775745 · Registry updated 2026-02-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | B-cell neoplasm, Blood Protein Disorders, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Waldenstrom macroglobulinemia, cardiovascular disorder, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-02-13 | NCT04775745 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Newave Pharmaceutical Inc | 5 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Duke Univerisity | Durham | United States | 1 |
| Huntsman Cancer Institute, University of Utah | Salt Lake City | United States | 45 |
| Ohio State University | Columbus | United States | 169 |
| University of Cincinnati | Cincinnati | United States | 24 |